University of Chicago
Current clinical trials testing the combination of immunotherapy with radiotherapy.
Inclusion Criteria: * Disease-Related Criteria * Patients must have histologically or cytologically confirmed metastatic or recurrent non-small cell lung cancer (NSCLC) with progression on prior immunotherapy * The patient's disease is eligible for SOC treatment with immunotherapy or chemotherapy. * Patients must have measurable disease per RECIST v1.1, defined as at least one lesion that can be accurately measured in at least one dimension with longest diameter ≥10 mm (or ≥15 mm short axis for lymph nodes) by CT or MRI * Patients must have at least one lesion that meets criteria for…
Participant will receive an FDA approved immunotherapy according to usual routine practice.
Description something along the lines of Participant will receive an FDA approved chemotherapy according to usual routine practice.
Participant will receive radiotherapy according to usual routine practice.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.